Table 1.

Clinical information cohort 1

Patient ID	Sample		PAM50 subtype	ER	PR	HER2	HER2 CNV (exome data)	AdjCT	AdjHT	AdjRT	DFI	Relapse site	Relapse to death
P1	Primary Tumor Metastasis	3	NA Luminal B	+ -	+ -	- -	HER2- HER2-	+	+	+	3.3	liver	3.2
P2	Primary Tumor Metastasis	3	NA Basal like	- NA	- NA	- NA	HER2- HER2-	+	–	+	1.4	lymph	4.9
P3	Primary Tumor Metastasis	3	Na Luminal B	- -	+ -	- NA	HER2- HER2-	–	–	+	4.1	liver	1.5
P4	Primary Tumor Metastasis	3	NA Basal like	- NA	- NA	NA NA	HER2+ (CN 3.5) HER2+ (CN 3.5)	+	+	+	8.1	lung	6.0
P5	Primary Tumor Metastasis	N/A	NA Luminal A	+ +	- -	- NA	HER2- HER2+ (CN 2.5)	–	+	+	3.5	liver	5.7
P6	Primary Tumor Metastasis	3	NA HER2 enriched	+ +	+ -	NA -	HER2- HER2-	+	+	+	2.6	lymph	1.1
P7	Primary Tumor Metastasis	2	NA Normal like	+ +	+ -	NA -	HER2- HER2-	+	+	+	4.8	skin	0.8
P8	Primary Tumor Metastasis		NA NA	+ +	+ +	- -	HER2+ (CN 2.4) HER2- (CN 0.8)	+	+	+	5 a	liver	0.7
P9	Primary Tumor Metastasis		NA NA	- -	- -	NA -	HER2- HER2-	+	–	+	11 a	breast	NA
P10	Primary Tumor Metastasis		NA NA	+ +	+ +	- -	HER2- HER2-	+	+	+	4 a	bone	0.4

Receptor status by IHC (immunohistochemistry)

ER estrogen receptor, PR progesteron, HER2 Her2 receptor status, HER2 CNV amplification of Her2 derived from exome data, AdjCT adjuvant chemotherapy, AdjHT adjuvant hormone therapy, AdjRT adjuvant radiotherapy, DFI disease free interval (months); Relapse to death (months)

^aapproximated as time from primary tumor surgery date to relapse diagnosis date